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Clear cell renal cell carcinoma (ccRCC) displays a highly varying clinical progression, from
slow growing localized tumors to very aggressive metastatic disease (mRCC). Almost a
third of all patients with ccRCC show metastatic dissemination at presentation while
another third develop metastasis during the course of the disease. Survival rates of mRCC
patients remain low despite the development of novel targeted treatment regimens.
Biomarkers indicating disease progression could help to define its aggressive potential
and thus guide patient management. However, molecular markers that can reliably assess
metastatic dissemination and disease recurrence in ccRCC have not been recommended
for clinical practice to date. Liquid biopsies could provide an attractive and non-invasive
method to determine the risk of recurrence or metastatic dissemination during follow-up
and thus assist the search for surveillance biomarkers in ccRCC tumors. A wide spectrum
of circulating molecules have already shown considerable potential for ccRCC diagnosis
and prognostication. In this review, we outline state of the art of the key circulating analytes
such as cfDNA, cfRNA, proteins, and exosomes that may serve as biomarkers for the
longitudinal monitoring of ccRCC progression to metastasis. Moreover, we address some
of the prevailing limitations in the past approaches and present promising adoptable
technologies that could help to pursue the implementation of liquid biopsies as a
prognostic tool for mRCC.
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INTRODUCTION
Kidney cancer is the seventh most frequent cancer worldwide and is responsible for nearly 100,000
deaths each year. Clear cell renal cell carcinoma (ccRCC), the most common subtype of RCC,
accounts for almost 75% of detected cases and is therefore far more frequently studied than the rarer
histologies (1). One of the landmark events in its tumorigenesis is loss of the short arm of
chromosome 3p on which the VHL tumor suppressor is encoded. This is often concurrent with a
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gain of chromosome 5q resulting in the generation of a small
population of tumor-initiating cells (2). Consequently, the
inactivation of the second copy of the VHL gene heralds the
development of clinically aggressive ccRCC (2). Genetically,
ccRCC is characterized by high intra-tumor heterogeneity (3,
4). Recurrent somatic mutations found in ccRCCs occur in the
epigenetic regulators PBRM1, SETD2 and BAP1, all of which are
also located on chromosome 3p and are therefore prone to
inactivation similar to VHL (5). These specific genetic changes
are reflected at the RNA and protein levels, for instance, by
activation of the HIF-pathway and a corresponding increase in
expression of angiogenesis-related mRNA signatures and
hypoxic signaling, which are direct consequences of VHL
inactivation (6). Extensive metabolic reprogramming is another
result of the genetic changes that occur during ccRCC initiation
and progression and this is increasingly recognized to correlate
with aggressive disease (7). This is exemplified by the
inactivation of the pyruvate dehydrogenase complex (PDC)
which in turn impairs the Krebs cycle and oxidative
phosphorylation resulting in a metabolic shift toward glycolysis
(8). Importantly, metabolic rewiring in ccRCC has been shown to
induce HIF-signaling independent of VHL through signaling
pathways that involve for example mTOR and MET. This
metabolic distortion could influence epigenetic changes and
chromatin dysregulation, contributing to the aggressiveness of
the tumor (9).
In contrast to primary ccRCCs, which often show a high
number of subclonal drivers, metastatically progressed disease
sites have a more homogenous molecular landscape. They
contain fewer somatic mutations indicating the excerption of
only those clones that are metastatically competent. Conserved
trajectories have been identified to lead to metastasis, with
PBRM1 mutations often predicating dissemination (10). Other
hallmark genomic alterations that lead to metastasis are the
loss of chromosome 9p and 14q. Interestingly, microRNA
(miRNA) signatures are also disparate between the primary
and metastatic sites, with several miRNAs associating with
worse patient outcomes (11). A prominent example is miR-
30c, which showed decreased expression in metastatic disease
corresponding to lower progression-free survival (PFS). This
finding is in line with its observed function in cell adhesion
and invasion (12).
Importantly, the clinical diagnosis of ccRCC is most often
incidental. Almost 30% of ccRCC patients already present with
metastatic disease while another 30% develop metastasis later
during the course of the disease (1). The prognosis for metastatic
RCC (mRCC) is still relatively dismal with a variable spectrum of
overall survival (OS) times ranging from less than 6 months to
more than 5 years (13). It is therefore clear that accurate
prognostic and risk identification strategies that enable the
early prediction of recurrences could impact ccRCC clinical
management (Figure 1). In fact, the likelihood of a favorable
response to treatment is superior with limited metastatic burden
(14). However, no specific molecular marker has been
recommended for this clinical use to date (15). Liquid biopsies
are emerging as a minimally invasive, rapid, and cost-effective
tool to determine cancer markers in biological liquids such as
blood or urine (Figure 1) (16, 17). The source for these potential
FIGURE 1 | Longitudinal monitoring of disease progression via liquid biopsy. Liquid biopsy presents as a minimally invasive prognostic technique, allowing the
surveying of disease burden and progression in patients through biological liquid samples such as blood and urine. ccRCC patients, who tend to show high
variability in disease progression, could benefit from better therapeutic response and PFS (Progression-free survival) with continuous follow-up of tumor molecular
profiling through analyzing tumor-specific circulating biomarkers over time. Plasma and urine samples could be collected over several time points and profiled via
ultra-sensitive analytical techniques, helping guide clinical management strategies.
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biomarkers is the “circulome”, which refers to the molecules
released into circulation from all tissue, including the tumor
tissue. Therefore, liquid biopsies may contain tumor-specific
information in the form of circulating tumor cells (CTCs),
circulating tumor DNA (ctDNA), circulating tumor RNA
(ctRNA), secreted proteins, extracellular vesicles, metabolites,
and tumor-educated platelets. Currently, a small number of non-
invasive blood tests that detect ctDNA are used as companion
diagnostic tool for cancers such as non-small cell lung carcinoma
(NSCLC), prostate and colorectal carcinoma. These tests are
mainly used as rationales for treatment decisions, for example to
detect activating mutations in the Epidermal Growth Factor
Receptor (EGFR) that can be treated by administering
Osimertinib in patient with NSCLC (18). Alongside, several
liquid biopsy tests are under investigation in clinical trials as
reviewed by Heidrich et al. (19). Among the putative markers
with prognostic relevance in mRCC, ctDNA, ctRNA, proteins
and exosomes are currently under heavy examination. In this
review, we will provide a brief overview of the recent
developments in the identification of circulating biomarkers
that are indicative of a metastatic lesion and which allow the
identification of disease recurrence in ccRCC patients. Moreover,
we present several novel and promising technologies that could
overcome some of the current limitations of liquid biopsy
analysis that have been roadblocks to implementing them as a
prognostic tool with clinical utility (Figure 2).
CIRCULATING TUMOR DNA
The highly aggressive and vascularized nature of ccRCC
prompted the intuitive expectation that tumor material, such
as DNA, could be shed into circulation constituting a powerful
tool to profile the tumor genome bypassing the need for a tissue
biopsy. We have identified a number of studies, using the search
terms “Renal cell carcinoma” and “Circulating tumor DNA”
from public databases, that have investigated such possibilities
(Table 1). Early reports paved the way by demonstrating the
feasibility of genetic analysis from liquid biopsies, initially
proposing the use of cell-free DNA (cfDNA) concentration
and fragmentation as a guide for predicting and following the
progression toward mRCC. Repeatedly, cfDNA concentrations
were shown to be significantly higher in patients with advanced
or metastatic disease compared to healthy individuals and
patients with localized tumors (Table 1). Interestingly, analysis
of the housekeeping gene ACTB as a surrogate measure of
cfDNA concentration showed a consistent and significant
elevation in RCC patients compared to healthy controls (21).
Additionally, Wan et al. reported that the average plasma cfDNA
level was significantly higher in metastatic tumors than in
localized disease indicating that they could even be reflective of
ccRCC progression (22). Even though these observations are
noteworthy, both studies reported only moderate sensitivity and
specificity for the alterations and thus further validation is
required to clarify the clinical benefit of cfDNA concentrations
as a circulating biomarker.
Fragmentation of cfDNA has also been studied as a diagnostic
and prognostic marker in RCC patients (28, 30). Several groups
performed these analyses using marker DNA fragments from
genes like ACTB, GAPDH and APP as well as Alu short
interspersed nucleotide elements and the mitochondrial DNA
fragments Mito-1 and Mito-2 (20, 21, 24). Lu et al. could
correlate shorter cfDNA fragments of the gene amyloid beta
(A4) precursor protein (APP) with prognostic factors for
recurrence-free and OS in patients with ccRCC and the cfDNA
FIGURE 2 | Tumor-specific circulome and technologies used for their analysis. Tumor-specific circulating biomarkers can include several molecules involved in
tumorigenesis and tumor progression. Analytes that have been studied as potential biomarkers so far are depicted. Using a variety of techniques, their quantification
at a single time point may allow disease staging and prognostication (cfDNA. cell-free DNA; cfRNA. cell-free RNA; cfNucleosomes. cell-free nucleosomes; CTCs,
circulating tumor cells; ctDNA, circulating tumor DNA; qPCR, quantitative polymerase chain reaction; ddPCR, droplet digital polymerase chain reaction; NGS, next-
generation sequencing; cfMeDIP-seq, cell-free methylated DNA immunoprecipitation sequencing; cfChIP-seq, cell-free chromatin immunoprecipitation sequencing;
ctRNA, circulating tumor RNA; ELISA, enzyme-linked immunosorbent assay; MS, Mass spectrometry; FACS, fluorescence-activated cell sorting).
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TABLE 1 | Circulating Tumor DNA.
Reference Evaluation method No of Patient samples Results
Gang et al. (20) qPCR Serum of 36 ccRCC patients
and 42 healthy controls
• Significant association between cfDNA integrity and tumor size and stage
• A significant difference in cfDNA fragmentation between pre and post-nephrectomy
samples was observed
Hauser et al. (21) qPCR Serum of 35 RCC patients
(29 ccRCC patients) and 54
healthy controls
• Amplified ACTB384 and ACTB106 fragments were significantly higher in RCC group
compared to healthy controls (ACTB-384: 1.77 vs. 0.61 ng/ml, p = 0.0003; ACTB-
106:.31 ng/ml vs. 0.77 ng/ml p = 0.003).
• cfDNA threshold levels to distinguish between RCC patients and healthy individuals
were 1.03 ng/ml for ACTB-106 (68.6% sensitivity and 70.4% specificity) and 1.70 ng/
ml for ACTB-384 (57.1%, sensitivity and 81.5% specificity)
• The significant higher level of ACTB384 in RCC patients indicates that cell-free serum
DNA is fragmented to a higher degree in cancer patients. Cell-free DNA levels of
ACTB384, ACTB106 and DNA integrity did not correlate with clinical parameters such
as tumor stage and grade
Wan et al. (22) qPCR Plasma of 92 ccRCC
patients, 44 healthy controls
• Decrease in cfDNA concentration in plasma samples following nephrectomy.
• Higher cfDNA levels in patients with metastatic disease (6.04ng/ml ± 0.72) when
compared to patients with localized disease (5.29 ± 0.53, p = 0.017) or healthy
controls (0.65 ± 0.29, p < 0.001)
• Increased cfDNA levels were associated with shorter recurrence-free survival
• Pre-treatment level of plasma cfDNA could predict recurrence with a sensitivity of
70.6% at specificity of 71.2%
Bettegowda
et al. (23)
NGS Plasma of 5 mRCC patients • <50% patients had detectable ctDNA
Lu et al. (24) qPCR Plasma of healthy individuals
(n = 40), non-metastatic (n =
145), and metastatic (n = 84)
ccRCC patients
• The mitochondrial cfDNAs Mito-1 and Mito-2 were higher in metastatic than in non-
metastatic patients and controls.
• Mito-1 and Mito-2 fragment concentration significantly correlated with Fuhrman grade
(rs = 0.209 and 0.206, p = 0.0121 and 0.014, respectively)
• APP-3 fragment concentration decreased in both ccRCC groups
• The cfDNA integrity decreased from controls to metastatic patients.
Corrò et al. (25) NGS Plasma and serum samples
of 9 ccRCC patients
• It was not possible to identify genetic alterations such as the VHL mutation in ccRCC
plasma without prior knowledge of patient-specific mutation profiles from primary
tumor tissue
Maia et al. (26) NGS- Gaurdant360
panel
Plasma from 34 RCC patients
(26 ccRCC patients)
• ctDNA was detected in 18 late-stage or mRCC patients (53%) with a median of 2 GAs
per patient. VHL (n = 5) and TP53 (n = 7) were the most frequent GAs.
• Patients with detectable ctDNA had significantly higher tumor size (8.81 vs. 4.49 cm;
P = 0.04)
Pal et al. (27) NGS - Guardant360 Plasma from 220 mRCC
patients
• Using an approach with great sensitivity to mutant cfDNA fragments at below 1%,
GAs were detected in 79% patients. Most frequent GAs were TP53 (35%), VHL (23%),
EGFR (17%), NF1 (16%), and ARID1A (12%).
• Mutations from non-RCC related somatic expansions like CHIP were not excluded
• 55% of variants were of unknown significance
• 45% of SNVs and indels were characterized with known significance. Distribution of




qPCR Plasma from 92 ccRCC
patients and 41 healthy
controls
• cfDNA concentration significantly higher in ccRCC group vs. healthy control (3803 vs.
2242 copies/ml, p < 0.001) and increased with TNM staging.
• Median cfDNA fragment size in ccRCC group significantly shorter vs. healthy control
and negatively associated with PFS
• cfDNA showed 63% sensitivity and 78.1% specificity as diagnostic marker in ROC
curve analysis
Smith et al. (29) Whole genome/
exome sequencing
MonRec study (43 metastatic
RCC patients treated with
multiple systemic therapies
and longitudinal follow-up)
and 90 patients from
DIAMOND study (samples
taken either prior to surgery
or during progressive disease)
• RCC is a ctDNA low malignancy, detection rates of ctDNA in patient plasma are ~30%
using an untargeted sequencing strategy
• A sensitive personalized approach which is based on prior knowledge of individual
tumor-specific mutations from matched tumor tissue could detect plasma ctDNA in
~50% of patients,
• ctDNA detection in plasma was more frequent amongst patients with larger tumors






Plasma of 53 ccRCC patients • Targeted sequencing was carried out using plasma cfDNA and ctDNA
• In 30% patients, somatic mutations were detected in cfDNA. Most frequently detected
mutations included TP53 (n = 6), BAP1 (n = 5), VHL (n = 5), TSC1 (n = 4), and SETD2
(n = 3.
• ccRCC patients with detectable ctDNA showed shorter fragment sizes of cfDNA.
(Continued)
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integrity index calculated based on the ratio of these fragment
concentrations showed a decreased trend from controls to
mRCC patients (24). Similarly, mitochondrial and Alu
elements showed increased fragmentation and lower cfDNA
integrity in RCC patients. However, when analyzing DNA
integrity using ACTB and GAPDH as markers, cfDNA
fragmentation was increased in RCC compared to controls (20,
21). While it has been shown that cfDNA fragmentation could be
a valuable biomarker, further work needs to clarify which genetic
elements have to be selected to ensure a complete visualization of
the cfDNA fragment landscape and its diagnostic and prognostic
potential (24). ctDNA has been identified in renal cancer patients
of all stages but the probability of detection increased with the
tumor size indicating that advanced disease stages may be better
reflected in liquid biopsies (29). However, a number of studies
reported ctDNA to be much less abundant in liquid biopsy
samples from RCC patients compared with those from other
cancers and several groups showed that ccRCC-specific ctDNA
could be detected in only about 30%–50% patients (23, 25, 26, 29,
31). In a recent study, Bacon et al. used the Roche SeqCap EZ
Human Oncology Panel to analyze the coding regions of 981
cancer-related genes in plasma cfDNA of 55 mRCC patients (31).
Even this comprehensive analysis could only detect evidence for
RCC-derived ctDNA, such as a somatic mutation in more than
one established RCC genes, in a third of the patients. It is
noteworthy that this was the first study that accounted for
non-RCC specific somatic clones in liquid biopsies which can
stem from clonal hematopoiesis of indeterminate potential
(CHIP) by analysis of patient-matched leukocyte DNA. This
could have decreased the sensitivity toward cfDNA mutations
while increasing the sensitivity to RCC-derived ctDNA
mutations. In addition, this study reveals that the blood-borne
ctDNA fraction was as low as 3.9%, which is considerably less
than in metastatic breast or lung cancer (32, 33).
Two other recent studies have reported higher numbers of
ctDNA-positive patients. One of the largest studies by Pal et al.,
which included 220 mRCC patients, promisingly reported RCC-
specific alterations in genes such as VHL, TP53, EGFR, NF1, and
ARID1A in almost 80% of the patients when using a driver gene
deep sequencing approach, with great sensitivity to mutant
cfDNA fragments (<1%) (27). This apparent discrepancy in
detecting tumor-specific mutations in the aforementioned
study could be due to two factors: Although Pal et al. analyzed
a larger cohort, only 56% of the samples were histologically
characterized, of which 70% were classified as ccRCC. In
comparison, the cohort used by Bacon et al. was completely
histologically classified and contained 85% ccRCC patients.
Moreover, Pal et al. did not account for non-RCC specific
somatic clones which may be a rather large contributor to the
genetic alterations observed in RCC liquid biopsies.
A second recent and sophisticated pipeline to detect cell-free
tumor DNA in RCC patients’ plasma and urine samples was
introduced by Smith et al. and was termed as a “personalized
method” of ctDNA sequencing. Similar to other studies,
sequencing of plasma cfDNA alone could identify ctDNA in a
third of the RCC patients, including those with mRCC. However,
when the personalized method that was based on prior
sequencing of the primary tumor tissue and subsequent
assessment of the known mutations in corresponding liquid
biopsies was applied ctDNA detection rates improved to ~50%
(29). In addition, in a small cohort of patients, the authors could
show the prognostic value of ctDNA analysis by revealing that
longitudinal plasma sampling could track disease progression.
Another important finding from this study is that plasma ctDNA
represented 90% of the disparate mutations found in multiple
biopsy regions from individual tumors of two well characterized
ccRCC patients and thus indicated that ctDNA could be used to
circumvent tumor sampling bias that might be present in
TABLE 1 | Continued
Reference Evaluation method No of Patient samples Results
• cfDNA fragments with SETD2, BAP1, and NF2 mutations were significantly shorter
than wild type cfDNA fragments.
• Detectable ctDNA and cfDNA size associated with poor PFS and CSS (long vs. short,
P = .004, P = .011 and high vs. low, P = .317, P = .127, respectively)
Bacon et al. (31) NGS - Roche
SeqCap EZ Human
Oncology Panel
Plasma from 55 mRCC
patients
• 33.3% of patients showed evidence for the presence of ctDNA, exhibiting a somatic
mutation in ≥1 established RCC gene. The estimated ctDNA fraction was 3.9% and
median VAF = 3.6%.
• Most commonly mutated genes include VHL (41%), BAP1 (29%), and PBRM1 (17%).
Mutation profiles were highly concordant between ctDNA and corresponding tissue
(77% of mutations were shared)
• 11 patients were identified harbouring non-RCC specific cfDNA somatic mutations and
lower VAF = 1.5%, arising from CHIP
• 22 CHIP-related mutations in all patient samples, median VAF = 2.15%. ctDNA
positive patients had lower PFS and OS
• Evidence of somatic expansions unrelated to RCC, such as CHIP were detected in
43% of patients.
List of original articles cited in this section, with the main results summarized. The classification in RCC subtypes was not unequivocally done in all studies. Since ccRCC accounts for the
majority of RCC cases, reports that did not state specifically which histological subtype was analyzed were also included. BRT, Benign renal tumors; cfDNA, Cell-free DNA; CHIP, clonal
hematopoiesis of intermediate potential; ctDNA, Circulating tumor DNA; CSS, Cause-specific survival; GA, Genomic alterations; NGS, Next-generation sequencing; qPCR, Quantitative
real-time polymerase chain reaction; PFS, Progression-free survival; VAF, Variant allele frequency; OS, Overall survival.
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conventional tissue biopsies. This is an attractive approach to
overcome the well-established tumor heterogeneity present in
ccRCCs (34).
Taken together, a number of studies indicate RCC as a
ctDNA-low malignancy by showing that only 30%–50% of
patients benefitted from characterization of ccRCC-specific
ctDNA using the currently available profiling technologies (23,
25, 26, 29, 31). Despite these drawbacks, ctDNA was detected
more frequently in plasma amongst patients with larger tumors
and hence longitudinal sampling could be used to monitor the
course of the disease at least in a subset of advanced patients.
Even though cfDNA analysis does not seem to enable
straightforward surveillance at the moment, novel technologies
could significantly improve this situation in the future.
PROTEINS AND ONCOMETABOLITES
Liquid biopsies could help to further investigate the proteomic
landscape reflecting the changes triggered, for example, by
extravasation of the ccRCC into circulation. Blood, abundant
with proteins, is an inviting medium for exploring disease-
related markers but it is technically challenging to mine
tumor-specific signatures amidst highly abundant plasma
proteins and other soluble factors. Studies identified with a
keyword search for “renal cell carcinoma”, “liquid biopsy or
plasma”, “protein or proteome” were further selected based on
their diagnostic and prognostic value and are discussed in this
section. A number of these studied utilized different
experimental approaches in order to identify proteins with
differential abundance in RCC plasma or serum relative to
controls (Table 2; Please refer to Clark and Zhang Clin
Proteom 2020 (52) for a comprehensive review). Historically,
one of the most extensively studied proteins in this context is the
Kidney Injury Molecule 1 (KIM1). KIM1 levels were found to be
significantly increased in RCC patients (36). In fact, high grade
ccRCCs showed an almost 7-fold increase in KIM1 abundance
and mRCC patients displayed particularly high KIM1 levels in
their plasma (47, 49). Despite the rather widespread expression
of KIM1 in several renal diseases (53), circulating KIM1 showed
83% specificity in detecting early stage tumors with an increase to
97% specificity in later stages (47). While this makes it a
promising biomarker, further studies need to validate the
clinical utility of KIM1 as a ccRCC-specific circulating protein.
Acknowledging the involvement of VHL mutations in ccRCC
tumorigenesis, proteins downstream of the hypoxia-pathway
represent a class of interesting soluble markers. For instance
HIG2, a hypoxia inducible protein, was elevated approximately
3-fold in the plasma of RCC patients in an ELISA-based study
and its abundance decreased drastically after nephrectomy (38).
CAIX, one of the most prominent targets of the VHL-HIF-
pathway, also emerged as a potential biomarker showing
increased protein concentrations and activity in the plasma of
ccRCC patients compared controls (45). Similarly, high IMP3
levels have been observed in RCC patients and correlated with
the development of distant metastasis (48). Additionally, high
levels of soluble CD27 were detected in sera of ccRCC patients
and in vitro analyses suggested that this was triggered by the high
expression of the HIF-target gene CD70 (43). These examples
illustrate how the knowledge of ccRCC-specific cellular
aberrations can be leveraged in the search for candidate
biomarkers. Nevertheless, looking beyond the VHL-HIF-
pathway, the TNF-related apoptosis-inducing ligand (TRAIL)
was identified as a potential biomarker showing a 2-fold decrease
in RCC patient sera and being highly predictive of venous
invasion and metastasis (41).
Despite their initial promise, none of these circulating protein
markers were clinically approved. Subsequently, large-scale
proteomic technologies were utilized in order to provide a
deeper characterization of ccRCC-specific protein assisting the
search for candidate liquid biomarkers (Figure 2). An earlier
study could distinguish RCC patients from non-RCC and
healthy controls by using SELDI-TOF and applying pattern
analysis based on five proteins with masses in the range of
3,900–5,900 Da (35). Similar studies have identified other peaks
at 4,151 and 8,968 m/z that significantly differed between RCC
and healthy controls and had an overall specificity of 80% (37).
These even provided evidence for the utility of individual
proteins including factor XIIIB, complement C3, misato
homolog 1, hemopexin, alpha-1-B-glycoprotein (39) and
HSC71 (44) as RCC-specific soluble biomarkers. Moreover,
using MALDI-TOF, RNA-binding protein 6 (RBP6), tubulin
beta chain (TUBB), and zinc finger protein 3 (ZFP3) were found
to reduce following surgical intervention (40). Taken together,
these findings underscore the opportunity to use the plasma
proteome for longitudinal disease monitoring.
Much like it has been utilized with ctDNA, linking liquid
biopsy protein profiles to those of the primary RCC could
provide important complimentary data for the search of
candidate biomarkers. In an interesting discovery study, White
et al. used LC-MS/MS analysis to identify differentially expressed
proteins in ccRCC compared to normal kidney tissue (42). From
this analysis, heat shock protein beta-1 (HSPB1/Hsp27) emerged
as a promising candidate and consequently the utility of Hsp27
as a useful non-invasive marker was confirmed in patient sera.
Besides being elevated in serum and urine of ccRCC patients,
Hsp27 was also associated with high grade (Grade 3–4) tumors.
Finally, it makes intuitive sense that the assessment of soluble
immune-checkpoint proteins could have the added benefit of
predicting immunotherapy responses besides their diagnostic or
prognostic potential alone. Soluble factors such as sLAG3, sPD-
L2, sBTLA, and sTIM3 were observed in higher concentrations
in ccRCC patients and were significantly correlated with survival,
death-risk and recurrence (50). Moreover, these proteins have
already been developed as biomarkers for immune therapy
prediction in several other cancer types (54). Apart from the
proteome, other oncometabolites originating from metabolic
processes such as amino acid metabolism, hormone synthesis
and lipid transport including leucine, N-lactoyl-leucine, N-
acetly-phenylalanine, hydroxylprolyl-valine, cortolone, and
testosterone have been nominated as potential liquid
biomarkers in RCC patients (46, 51). A panel consisting of the
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TABLE 2 | Proteins and oncometabolites.
Reference Evaluation method No of Patient samples Results
Won et al. (35) SELDI-TOF MS/MS Serum of 15 RCC patients,
15 patients with other
urological malignancies and 6
healthy controls
• 119 mass peaks were identified from all samples. Bioinformatics analysis using a
predictive classifier (decision tree) was constructed with 5 distinct masses (3,900,
4,107, 4,153, 5,352, and 5,987 kDa)
• Decision tree correctly predicted the diagnosis of 85.7% of test samples
(Sensitivity = 87%, specificity = 85%)
Han et al. (36) Western blot and
ELISA
Urine of 42 RCC patients • KIM1 was elevated in RCC urine samples
• Upon examining association between KIM1 levels and RCC, Urinary KIM1 of
concentrations higher than 0.1 ng/ml was associated with a >36-fold risk of
RCC, 82% sensitivity, and 90% specificity
• Urinary KIM1 levels decrease after surgical removal of the tumor
Hara Tomohiko et al.
(37)
SELDI-TOF MS/MS Serum from 40 RCC
samples, 44 healthy controls
and 5 patients with
pyelonephritis
• Significantly prominent mass peaks of 4,151 and 8,968 m/z were found in RCC
samples
• Simultaneous recognition of both peaks discriminated RCC samples from
controls at 89.5% sensitivity and 80% specificity
• Stage I RCC could be discrimination from healthy or later stage at 88.9%
sensitivity using both mass peaks.
Togashi et al. (38) ELISA Plasma of 32 RCC patients,
20 healthy controls and 10
chronic glomerulonephritis
patients
• Higher plasma HIG2 in RCC (~2.5-fold increase)
• Decreased HIG2 post-surgery in stage I and stage II
Xu et al. (39) 2D gel electrophoresis,
MALDI-TOF MS/MS
Serum of 20 RCC patients
and 20 healthy controls
• Analysis of serum from diseased and healthy patients identified 19 differentially
expressed proteins
• Finally, 6 proteins were identified with a significant Mascot score (>66): factor XIII
B, complement C3, complement C3 precursor, hemopexin, and alpha-1-B-
glycoprotein.
Yang et al. (40) ELISA Plasma samples from 68
RCC patients and 39 healthy
controls
• Plasma VEGF levels were significantly higher in RCC patients.
• VEGF levels associated with lymph node invasion and/or metastases
Toiyama et al. (41) ELISA Serum of 84 RCC patients
and 52 healthy controls
• TRAIL levels were lower in RCC patients (55.9 vs. 103.1 pg/ml; P = 0.019)
• Decreased TRAIL expression associated with lymph node metastasis, distant
metastasis and venous invasion
White et al. (42) LC-MS/MS, western
blotting
Serum of 54 RCC patients
and 36 normal individuals;
urine of 21 RCC patients and
9 normal individuals
• Using proteomic analysis, 55 proteins were identified to be significantly
dysregulated in ccRCC compared to normal kidney tissue
• Heat shock protein beta-1 (HSPB1/Hsp27) was confirmed in two independent
sets of patients by western blot and immunohistochemistry
• Hsp27 was elevated in the urine and serum from RCC patients
• Higher tumor grades (grade III-IV) were associated with higher Hsp27 expression
in patient serum (p = 0.013)
Ruf et al. (43) ELISA Serum of 54 ccRCC patients
and 17 healthy controls
• High levels of soluble CD27 in patients with CD70-expressing ccRCC cells and
CD27+ Tumor infiltrating lymphocytes
• CD70 expression levels in tissue were not reflected in sera (n = 31)
Zhang et al. (44) Western blot, ELISA
and iTRAQ-labelled
MS/MS
Serum of 40 RCC patients,
10 healthy controls and 20
patients with other urological
malignancies
• 16 proteins increased >1.5-fold and 14 proteins decreased <0.67-fold in RCC
patients compared to controls.
• Quantification by western blot showed that HSC71 was significantly upregulated
in RCC sera (P = 0.0037)
• HSC71 was elevated in RCC sera when measured with ELISA (P = 0.0028 vs.
control, P = 0.0008 vs. non-RCC) and showed diagnostic value (AUC = 0.86 and
87% sensitivity at 80% specificity)
Lucarini et al. (45) Western blot, ELISA
and enzyme activity
assay
Plasma of 8 ccRCC patients,
8 BRT and 8 controls
• Plasma CAIX levels were significantly higher in ccRCC patients (p ≤ 0.005)
• CA IX activity was lower in healthy controls compared to ccRCC or BRT (kcat
5.57 × 104 s−1 vs. kcat 1.62 × 106 s−1 or 1.46 × 104 s−1)
Knott et al. (46) UPLC-MS/MS Serum samples from 5
ccRCC patients and 5
healthy controls
• Renal carcinoma cell lines were used to define a panel of 21 tumor-specific
metabolic features and these were assessed in human serum samples.
• 9 of these features were present in serum samples. A PCA model based on
these 9 feature panel provided showed diagnostic value, utilizing 2PCs at a total
variance of 70.87%
Kushlinskii et al. (47) ELISA Plasma of 99 ccRCC
patients, 14 BRT and 29
healthy controls
• KIM-1 levels are elevated in ccRCC patients and BRT
• KIM-1 levels could discriminate ccRCC at all stages: Stage I: 81% sensitivity;
Stage II-IV: 97% sensitivity
• KIM-1 levels correlated with tumor stage (stage 1/2 vs. stage 3/4)
Tschirdewahn et al.
(48)
ELSIA Plasma of 98 RCC patients
and 20 healthy controls
• Plasma IMP3 was elevated in RCC samples (20 ng/ml vs. 10 ng/ml median, p =
0.015)
(Continued)
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metabolites cortolone, testosterone and l-2-aminoadipate
adenylate was able to distinguish RCC patients from benign
renal tumors with 100% specificity at 75% sensitivity, indicating
an increased effectiveness in discrimination when combining
groups of biomarkers that are involved in disturbed metabolic
pathways (51).
Taken together, several studies have already investigated
RCC-specific metabolites and in particular proteins but a large
proportion of these have only examined patient samples in
comparison to healthy controls in order to delineate aberrant
expression patterns specific for RCC diagnosis. Even though
interesting markers have been nominated, information on the
prognostic value of many of these candidates is still lacking. In
addition, large-scale deep proteomic characterization has
revealed various potential biomarkers but due to the lack of
validation in clinical cohorts, very little can be used conclusively
to define a panel of markers for ccRCC monitoring. Novel mass
spectrometry and multi-marker based approaches are awaited to
provide more comprehensive insights and a deeper
understanding of potential secretory protein markers and their
prognostic value in ccRCC.
CIRCULATING RNA AND EXOSOMES
Cell-free RNA either enters the blood through active release from
cells in extracellular vesicles like exosomes or conjugated to
proteins (55–57). Coding RNA such as messenger RNA
(mRNA) as well as small non-coding RNAs like miRNA and
lncRNA have presented themselves as potential liquid biopsy
biomarkers (Figure 2). Search terms “renal cell carcinoma”,
“Circulating RNA or mRNA or miRNA or lncRNA” yielded
studies that were pruned to select a smaller collection with
relevant clinical value for ccRCC prognosis. So far, miRNAs
remain the most frequently studied class of RNA molecules
probably owing to the shorter half-life of mRNA and the
relative novelty of lncRNA (Table 3). Several miRNAs which
have previously been studied in the context of cancer progression
and development, have also been proposed as liquid biomarkers
in ccRCC. One of the most interesting examples is miR-210,
which is known to be regulated by the VHL/HIF-pathway (58)
and has emerged as a novel indicator for ccRCC tumor burden.
Elevated levels of circulating miR-210 have been reported in
patient sera and following nephrectomy they were observed to
TABLE 2 | Continued
Reference Evaluation method No of Patient samples Results
• IMP3 levels were higher in plasma from metastatic patients
• High IMP3 plasma levels were associated with OS and CSS
Scelo et al. (49) ELISA Plasma from 190 RCC
patients and 190 healthy
controls
• KIM-1 detected in 93% RCC samples and 70% controls
• Incident rate ratio for doubling of KIM-1 levels was 1.71
• 5-year risk of RCC increased with increased KIM-1 levels (low vs. high: 0.2% vs.
1.0%)
Wang et al. (50) Multiplex Luminex
assay
Plasma samples from 182
ccRCC patients
• High levels of soluble LAG3 were associated with an increased risk of advanced
disease (OR = 3.36, P = 0.002)
• High soluble PD-L2 concentration correlated with an increased risk of disease
recurrence (HR = 2.51, P = 9.33 × 10−4)
• Patients with high soluble BTLA and high soluble TIM3 showed an increased risk
of tumor-related death (6-fold increase) and decreased OS (log-rank P = 9.81 ×
10−8 and log-rank P = 6.29 × 10−5, respectively)
Zhang et al. (51) LC-M/MS Urine samples from 39 RCC
patients, 22 BRTs and 68
healthy controls
• 79 metabolites with differential abundance were identified.
• Pathway analysis showed disturbance in amino acid metabolism, including
phenylalanine metabolism, lysine degradation, lysine biosynthesis and histidine
metabolism in renal tumors
• 16 metabolites showed good diagnostic clinical value. Cortolone, testosterone
and l-2-aminoadipate adenylate levels could distinguish malignant from benign
tumors.
• A logistic regression model based on this panel of metabolites could discriminate
RCC patients from controls with a specificity of 100% and a sensitivity 75% in
the test cohort (n = 68).
• In an independent validation cohort, both sensitivity and specificity were 80%
(n = 49)
• 56 metabolites were differentially expressed between RCC and normal in this
validation cohort. Finally, a panel with aminoadipic acid, 2-(formamido)-N1-(5-
phospho-d-ribosyl) acetamidine and alpha-N-phenylacetyl-l-glutamine could
predict RCC specificity of 75% at 93% sensitivity (AUC = 0.885)
List of original articles cited in this section, with the main results summarized. The classification in RCC subtypes was not unequivocally done in all studies. Since ccRCC accounts for the
majority of RCC cases, reports that did not state specifically which histological subtype was analyzed were also included. AUC, Area under curve; BRT, Benign renal tumors; CSS, Cause-
specific survival; ELISA, Enzyme linked immunosorbent assay; iTRAQ, Isobaric tag for relative and absolute quantitation; HR, Hazards ratio; LC, Liquid chromatography; MALDI, Matrix-
assisted laser desorption/ionization; MS, Mass spectrometry; OR, Odds ratios; OS, Overall survival; PCA, Principal component analysis; TOF, Time of flight; SELDI, Surface-enhanced laser
desorption/ionization; UPLC, Ultra-performance liquid chromatography.
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Zhao et al. (58) qPCR Serum of 68 ccRCC
patients and 42 healthy
controls
• miR-210 showed high expression in ccRCC serum and could differentiate ccRCC patients from
healthy controls; 81% sensitivity, and 79.4% specificity
• miR-210 levels correlated with ccRCC stage and were reduced after nephrectomy.
Teixeira et al. (59) qPCR Plasma of 77 RCC
patients
• miR-221 and miR-222 were more abundant in RCC plasma (2−DDCt = 2.8, P = 0.028; 2−DDCt = 2.2,
P = 0.044, respectively).
• miR-221 levels were higher in plasma of metastatic patients than patients with no metastasis
(2−DDCt=10.9, P = 0.001) and high expression correlated with lower OS (48 vs. 116 months,
respectively; P = 0.024)
Wu et al. (60) qPCR Serum of 71 ccRCC
patients, 8 BRT, 62
healthy controls
• lncRNAs showed differential abundance: 13 lncRNAs were down-regulated and 1 lncRNAs was
up-regulated in ccRCC serum. The signature of lncRNA-LET, PVT1, PANDAR, PTENP1 and
linc00963 was highly specific and sensitive in discriminating between ccRCC and controls
• This 5-lncRNA signature was also correlated with all pathological stages of ccRCC (AUC = 0.85
and 0.8 for stage I and II-IV, respectively)
Li et al. (61) qPCR Urine of 75 ccRCC
and 45 healthy
controls
• Urinary miR-210 was significantly elevated in ccRCC samples and discriminated ccRCC from
healthy controls, 57.8% sensitivity, and 80% specificity.
• miR-210 levels decreased after surgical removal of the tumor
Petrozza et al. (62) qPCR Urine of 38 ccRCC
patients
• miR-210 was upregulated in ccRCC samples and levels significantly decreased after nephrectomy
Heinemann et al. (63) NGS- Small
RNA
sequencing
Serum of 86 ccRCC,
55 BRT, 28 controls
• 2588 miRNAs were detected from which 29 miRNAs were differentially expressed between healthy
and disease samples: 17 miRNAs were up-regulated and 12 miRNAs were down-regulated in the
tumor samples.
• Serum miR-122-5p and miR-206 (log2 fold change − 1.55; p = 0.002 and log2 fold change −
1.56; p < 0.001, respectively) were down-regulated in ccRCC sera. miR-122-5p and miR-206
could discriminate ccRCC from controls
• miR-122-5p significantly increased in mRCC
• Elevated serum miR-122-5p and miR-206 correlated with shorter PFS, CSS and OS
Liu et al. (64) qPCR Serum of 10 ccRCC
patients, 10 healthy
controls
• miR− 141−3p and miR− 508−3p were down-regulated while miR− 885−5p and miR− 592 were
up-regulated in ccRCC samples. All 4 miRNAs could discriminate RCC samples from healthy
donors (AUC = 0.73, 0.86, 0.91, and 0.78, respectively)
• The combinations of miR− 508−3p and miR− 885−5p analysis improved the discriminative power
between healthy and diseased samples (AUC = 0.9)
Simonovic et al. (65) qPCR Plasma from 10 mRCC
and 6 ccRCC patients,
7 healthy controls.
• CDK18 and CCND1 mRNAs were less abundant in the plasma of ccRCC patients (2.1 fold
change, p = 0.001 and 1.55 fold change, p = 0.039, respectively)
Exosomes
Raimondo et al. (66) LC-MS/MS Urine of 29 RCC
patients and 23 healthy
controls
• Proteomic analysis was performed on 9 urinary exosome pooled samples and led to the
identification of 261 proteins from control samples and 186 from RCC patient samples.
• Most of the identified proteins are membrane associated or cytoplasmic
• A panel of 10 proteins (CD10, CP, DPEP1, MMP9, EMMPRIN, CAIX, Syntenin 1, PODXL, AQP1,
DKK4) that were differently abundant in tumor and normal EVs were validated by immunoblotting
Butz et al. (67) qPCR 109 ccRCC patients,
24 BRT and 33 healthy
controls
• The combination of miR-126-3p and miR-449a or miR-24b-5p could distinguish ccRCC from
controls
Qu et al. (68) qPCR Plasma of 71 RCC
patients
• The non-coding transcript lncASR was increased in RCC patients
• lncASR levels decreased after nephrectomy and increased again upon relapse
Du et al. (69) qPCR 109 RCC patients • miR-190b, miR 26a-1-3p, miR-let-7i-5p, miR-145-3p, miR-200-3p, and miR-9-5p associated with
OS in an initial test cohort (n = 44)
• In an additional validation cohort, association with OS was verified for miR-let-7i-5p, miR-26a-1-3p,
and miR-615-3p.
Jingushi et al. (70) LC/MS,
Western
blotting
Serum of 19 ccRCC
patients and 10 healthy
controls
• Extracellular vesicles (EVs) directly isolated from surgically resected ccRCC tissues and adjacent
normal renal tissues were analyzed with quantitative LC/MS. This analysis identified 3,871 tissue‐
exudative EV proteins, among which azurocidin (AZU1) was highly enriched in tumor EVs (fold‐
change = 31.59).
• AZU1 content in EVs was significantly higher in ccRCC patients compared to those from healthy
donors.
• Subsequent functional analyses indicated that EV‐AZU1 could be engaged with vesicle‐mediated
hematogenous metastasis of RCC.
Zhang et al. (71) qPCR 82 ccRCC patients, 80
healthy controls
• Exosomal miR-210 and miR-1233 significantly higher in ccRCC, and higher in each stage
compared to normal
• miR-210 and miR-1233 significantly lower post-surgery
• miR-1233 had higher discriminatory capability with higher specificity and sensitivity than miR-210.
List of original articles cited in this section, with the main results summarized. AUC, Area under curve; CSS, Cause-specific survival; LC, Liquid chromatography; MS, Mass spectrometry;
NGS, Next-generation sequencing; OS, Overall survival; PFS, Progression-free survival; qPCR, Quantitative real-time polymerase chain reaction.
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decrease in the urine of disease-free patients during follow-up
(61, 62). Several other miRNAs still remain to be explored as
biomarkers in circulation. Studies in primary ccRCC tissue have
identified 65 miRNAs, including miR-215, which were
significantly different between patients with mRCC and
localized ccRCCs (72). Whether these miRNAs can indicate
metastatic dissemination of the primary tumor in liquid
biopsies has not been not investigated to date. Circulating
miRNAs that have already been implicated in predicting
mRCC include miR-122-5p, miR-206 (63), and miR-221.
Importantly, out of these miR-221 has also been shown to
significantly correlate with lower survival (59). In addition, the
combination of serum miR-508-3p and miR-885-5p could
differentiate ccRCC patients, and these miRNAs have been
implicated in the positive regulation of metabolic processes
such as inositol phosphate metabolism and in the Hippo and
Wnt signaling pathways that have been implicated in ccRCC
tumorigenesis (64). Studying these miRNAs in metastatic
patients and establishing their regulatory roles in ccRCC would
likely improve their value as a circulating biomarker.
Messenger RNA is a crucial intermediate in relaying genetic
changes to the protein level and may therefore reflect mutational
and regulatory changes in the tumor. However, technical
difficulties in detecting tumor-specific mRNA in patients’
blood has limited its development as a biomarker for disease
monitoring. Recently, novel sequencing technologies have
provided impetus to further investigate the potential of
circulating mRNA and consequently CDK18 and CCND1
messengers were shown to be downregulated in blood of
ccRCC patients (65) (Table 2). Similarly, an increase in lysyl
oxidase (LOX) expression marked metastatic samples from the
same cohort (65). In addition, circulating lncRNA (73), one of
the newer players in the field of small non-coding RNAs, also
showed promise as a RCC-specific biomarker. A signature of 5
lncRNAs (lncRNA-LET, PVT1, PANDAR, PTENP1, and
linc00963) could distinguish RCC samples from controls with a
specificity of 91% at 67% sensitivity in a training set independent
of stage classification. An increase to 76% sensitivity was
observed when the training set was limited to controls and
stage I ccRCC patients, indicating good discrimination even for
less advanced patients (60).
Exosomes are nanoscale secreted membrane-bound vesicles that
play a role in cellular communication by transferring signaling
molecules as packaged cargo. One of the most frequent cargo is
miRNA, while several other molecules including DNA, proteins and
other classes of RNAs are transported in exosomes as well (74).
Studied far more in urine than in blood, these vesicles are observed
to contain molecules that are capable of differentiating and
identifying ccRCC and mRCC. Comparable to circulating miR-
210, exosomal miR-210 was elevated in ccRCC patient sera and
could distinguish ccRCC patients from healthy individuals, albeit
only with a specificity of 62% (71). Considering that circulating
levels of miR-210 have been described as relevant biomarkers in the
context of cell-free analytes and as exosomal cargo, this is
nevertheless one of the more promising molecules warranting
further studies to assess its diagnostic and prognostic potential as
a liquid biomarker for the clinical routine. Several other exosomal
miRNAs or their combinations such as enumerated in Table 2were
also able to differentiate RCC patients from healthy controls and
supported the proposed use of exosomal cargo as potential
biomarkers in ccRCC (67, 69). Additionally the non-coding
transcript lncARSR (activated in RCC with Sunitinib Resistance)
that is transmitted via exosomes, showed increased levels in the
serum of RCC patients, decreased after tumor resection and
subsequently increased again during tumor relapse making it an
interesting candidate for non-invasive disease monitoring (68). A
small number of studies have investigated the potential of exosomal
protein markers (66, 70) giving first insights into their differential
abundance between healthy and tumor patients. Interestingly,
comprehensive protein cargo analysis by LC/MS revealed that
azurocidin (AZU1) was significantly enriched in tumor‐derived
exosomes and these may even play a functional role in driving
metastatic dissemination (70).
Despite the initial reports, neither lncRNA nor exosomal
miRNAs or proteins have been thoroughly investigated as
potential biomarkers for the metastatic disease yet. Large sample
volumes and complicated and expensive processing set-ups appear
as major roadblocks in this search. Therefore, technical advances are
needed to improve the current approaches and pave the way to
further investigate and translate RNA- or exosome-based cancer
detection in the clinical setting.
FUTURE AVENUES IN LIQUID BIOPSY
Evidently, the field of liquid biopsy analysis is quickly evolving and
has shown considerable promise for anticipating cancer
progression, for example in lung, breast and colorectal cancer
(75–77). However, currently there is still insufficient evidence for
the clinical utility of majority of the circulating molecules in many
advanced cancers as well as in ccRCC (78). Several approaches are
under heavy investigation and their successful implementation
could provide further rationales for using liquid biopsies as a tool
for ccRCC patient management (Figure 2). However, one of the
most important aspects for consideration in any further
developments is the need to validate the emergence of potential
liquid biomarkers in larger patient cohorts in order to consider
them as specific and sensitive non-invasive markers of clinical
utility. Currently, many interesting studies have sought to assess
differential features between samples from healthy and diseased
individuals. Significantly more work will be required to obtain a
deeper understanding of the prognostic potential of the candidate
markers as they should not only be prioritized based on their
discriminatory benefit but also for their value in disease
monitoring, e.g., to indicate metastatic dissemination.
One of the rather unexpected obstacles in developing a clinically
applicable liquid biopsy analysis platform was the low ctDNA
abundance that has so far hindered ctDNA from becoming a
simple alternative to tissue biopsy in diagnosing and tracking
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mRCC (23, 25, 26, 29, 31, 79). Nevertheless, mutant fragments
derived from RCC cells have been identified in patients’ plasma and
the mutations closely mirrored the known landscape of the primary
tumors (31). Several studies indicated that there are opportunities
for liquid biopsies in the longitudinal follow-up of ccRCC patients
provided additional improvements will be made in isolation and
detection approaches. Among the main challenges is the
concomitant presence of mutant fragments from non-RCC
somatic clones stemming, for example, from CHIP which was
identified as a main cause for the discordance between plasma
and tissue RCC samples (31, 79). Incorporating appropriate
controls such as white blood cell DNA could prove to be essential
to eliminate variants arising from such unrelated somatic
expansions. Combining personalized mutations identified from
archival tumor tissue is another attractive strategy that was
proposed to improve the sensitivity of ctDNA detection in mRCC
(25, 29, 79). Conversely, most recently, a novel approach that is
based on genome-wide mutational signal integration has challenged
the paradigm of increasing the sequencing depth of a limited set of
target genes for reliable ctDNA detection (80). By placing the
emphasis on broadening the mutational landscape, this genome-
wide single-nucleotide variant (SNV) detection platform showed
evidence for allowing ultra-sensitive detection even at low-
sequencing depths as well as enabling quantitative dynamic
monitoring of disease burden. Thus, this approach could prove to
be an attractive alternative to overcome the low ccRCC-specific
ctDNA abundance and significantly increase detection sensitivity in
the future.
Epigenetic regulation presents a wide avenue to explore ccRCC
specific patterns, particularly since chromatin remodelers are
among the most frequently altered factors. Based on the principle
that tumor cells acquire aberrant DNA methylation, cell-free
methylated DNA immunoprecipitation sequencing (cfMeDIP
Seq) was able to markedly improve sensitivity for detecting
patients with mRCC. The assessment of top differentially
methylated regions of the cell-free methylome could also
distinguish ccRCC and control samples (81). Since blood cfDNA
is derived from fragmented chromatin, it often remains associated
with histones that may contain evidence of the epigenetic landscape
of the cells they originate from (82, 83). Thus, circulating cell-free
nucleosomes could become interesting targets for observing
mRCC-specific changes in expression programs that are often
imposed by alteration in SETD2, PBRM1, or BAP1. Chromatin
immunoprecipitation sequencing of cell-free nucleosomes (cfChIP-
seq) has emerged capable of identifying cell-of-origin expression
marks as well as changes in gene activity and transcription in
gastrointestinal cancers (82). Extrapolating this to ccRCC could
open a new window to provide detailed information about the state
of the disease from liquid biopsy analysis.
Novel proteomic technologies will also bolster the
development of circulating biomarkers. To aid the acquisition
of ccRCC-specific peptides, pre-fractionation with the aim to
either remove high-abundance proteins or enrich certain
proteins could be employed. In addition, novel MS-based
proteomic approaches such as Microflow LC-MS/MS (84) and
Trapped Ion Mobility Spectroscopy (TIMS) (85) constitute
valuable technologies for biomarker discovery. These,
combined with higher throughput, will likely help to identify
mRCC-specific proteins in liquid biopsies. A promising impetus
for further studies in this domain was provided with the
identification of several proteins differing in abundance with
the infiltration of ccRCC into the renal vasculature using nano-
scale liquid chromatographic tandem electrospray ionization
mass spectrometry (nLC-ESI-MS/MS) for the proteomic
analysis of urine and plasma (86).
Circulating RNAs (circRNA) represent a newly discovered
class of small non-coding RNAs that have recently come into
light as potential biomarkers for kidney diseases. Studies
leveraging primary tissue collections have identified several
combinations of these circRNA that are capable of identifying
ccRCC (87, 88) and also correlated with tumor grade (80).
Importantly, circRNAs have already been discovered as
exosomal cargo in urine and plasma from patients with
Idiopathic Membranous Nephropathy (89), raising the
interesting possibility that these molecules could also be
studied as indicators of renal cancer. Exosomes show high
potential as a useful vehicle for tracking disease progression
and dissemination by virtue of their aiding intercellular
communication. Due to their small size and low density,
recovery from plasma or urine remains the limiting step
towards straightforward isolation, detection, and quantification
(90). A novel chemical affinity-based capture method has
been developed for extracellular vesicle isolation (EVtrap) from
plasma, which showed a 7-fold increase in capture compared to
ultracentrifugation and can potentially ameliorate this problem.
In a promising proof-of-concept study, phosphoproteomic
analysis of RCC plasma samples revealed several proteins
capable of distinguishing five RCC patients from five healthy
controls (91) indicating that EVtrap could be exploited to
develop additional markers for disease monitoring.
It is also becoming increasingly apparent that the best
definition of tumor status and prognosis may arise from the
simultaneous study of various complimentary constituents of the
circulome and thus, a multi-marker based approach may prove
to be useful toward developing reliable biomarkers for disease
surveillance (92). Harnessing the indicative potential of several of
the molecules described in this review together may in fact be key
to achieving prognostic utility in ccRCC liquid biopsy profiling.
CONCLUSION
Liquid biopsy analysis offers a range of complementary information
through the circulome and has the potential to cause a major
breakthrough in clinical oncology. In contrast to conventional tissue
biopsy, it may even be able to capture a larger amount of the
molecular heterogeneity described for ccRCCs and inform about
aggressive clones that have disseminated toward the metastatic
niche. Before this potential can be realized, a number of hurdles
remain but given the rapid pace of technological development there
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is an air of optimism regarding its utility, especially for monitoring
the metastatic progression in ccRCC patients.
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